Clinical Trial: A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation.

U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT07456046) titled 'A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation.' on March 03.

Brief Summary: This is a first-in-human (FIH) multicenter, open-label, dose-escalation Phase 1 clinical trial to evaluate safety, tolerability, pharmacokinectics (PK), pharmacodynamics (PD), and preliminary efficacy of D3S-003 in participants with advanced KRAS p.G12D mutant solid tumors.

Study Start Date: March 31

Study Type: INTERVENTIONAL

Condition: KRAS P.G12D

Intervention: DRUG: D3S-003

Oral

Recruitment Status: NOT_YET_RECRUITING

Sponsor: D3 Bio (Wuxi) Co., Ltd

Published by HT Digital Content...